Abbott Reports Second-Quarter 2013 Results - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Abbott Reports Second-Quarter 2013 Results


Abbott announced second-quarter 2013 financial results in a July 17 press release.  The company’s second-quarter adjusted diluted earnings per share (EPS) was $0.46, which was above the previous guidance range reported as $0.30. Abbott confirmed its full-year 2013 EPS guidance, which represents double-digit growth.

Since separating its proprietary pharmaceutical business into a separate company, AbbVie, in Jan. 2013, Abbott’s businesses include Diagnostics, Medical Devices, Nutrition, and Established Pharmaceuticals (i.e., generic medicines). Abbott’s second-quarter 2013 worldwide sales of $5.4 billion increased 4.2 percent on an operational basis, and were driven by 8.4 percent operational sales growth in Nutrition, including 18.4 percent international growth, and 7.6 percent operational sales growth in Diagnostics, including 9.1 percent international growth. 

Sales in Abbott’s Established Pharmaceuticals business increased 0.2 percent in the second quarter on an operational basis and decreased 2.3 percent on a reported basis, including an unfavorable 2.5 percent effect of foreign exchange. Abbott is focused on expanding its pharmaceuticals presence and building local product portfolios in 14 key emerging markets where access to quality healthcare is expanding. Sales in these key emerging markets increased 4.4 percent on an operational basis and 2.5 percent on a reported basis in the quarter, including an unfavorable 1.9 percent effect of foreign exchange. Sales in other markets decreased 3.4 percent on an operational basis and 6.4 percent on a reported basis in the quarter, including an unfavorable 3.0 percent effect of foreign exchange. As expected, sales growth in developed markets continues to be negatively impacted by macroeconomic conditions, including European austerity measures. Abbott expects Established Pharmaceuticals operational sales growth to improve over the course of the year, primarily driven by continued strong performance in Russia, along with acceleration of growth in India and Brazil due to portfolio expansion and execution of recent tender wins.

Worldwide sales in Abbott’s Medical Devices business increased 0.2 percent in the second quarter on an operational basis. Reported sales decreased 1.6 percent, including an unfavorable 1.8 percent effect of foreign exchange. On July 15, Abbott announced two acquisitions in its Medical Devices business: IDEV Technologies, which expands Abbott's endovascular portfolio, and OptiMedica, which provides an immediate entry point into the laser cataract surgery market.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here